In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDUFA III is a game changer for US industry, but concern grows over FDA funding

This article was originally published in Clinica

Executive Summary

The US devices tax naturally dominates US industry’s day-to-day thinking, but it’s not the only pressing issue on the agenda. AdvaMed’s chairman for the past year, David Dvorak, believes that the user fees legislation, MDUFA III, re-authorised in 2012 and running until 2017, will be a “game changer” for industry which will improve patient access to devices.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts